pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 11·1 min read
save

AMA and lawmakers challenge insurer AI denial practices, call for oversight

Jun 11, 2026·read at STAT ↗RegulatoryNeutral

The American Medical Association and several members of Congress are publicly opposing recent denials of care that rely on artificial‑intelligence algorithms used by insurers.

The Department of Health and Human Services’ Office of Inspector General has begun reviewing these AI‑driven denial practices, signaling heightened regulatory scrutiny.

Lawmakers are proposing legislation or hearings to ensure transparency and fairness in AI decision‑making, arguing that patients should not be denied treatment based on opaque algorithms.

The article also notes that mental‑health platform Talkspace has introduced a new chatbot service, reflecting broader interest in AI tools despite the controversy.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: AMA and lawmakers push back on AI care denials”

read at STAT ↗
442 words · retrieved Jun 11
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Psychiatry & CNS2HematologyType 2 Diabetes

related stories

  • Sep 23STAT+: UnitedHealth, CVS push back on Medicare plan to curb remote patient monitoringSTAT
  • Sep 21Behind the outcomes: How whole-patient support is reshaping oncology careBioPharma Dive
  • Sep 17Purer fentanyl won’t solve the U.S. overdose death crisis, study saysSTAT
  • Sep 15STAT+: Medicare to expand its pilot that pays for technology to manage chronic diseasesSTAT
  • Sep 4Opinion: The FDA removed the red tape around one of the best drugs for children with schizophrenia. But the fear remainsSTAT